中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
7期
848-849
,共2页
王志忠%杨斌%孙占鸿%胡叶暖
王誌忠%楊斌%孫佔鴻%鬍葉暖
왕지충%양빈%손점홍%호협난
失眠症%艾司唑仑%补肾益脑丸
失眠癥%艾司唑崙%補腎益腦汍
실면증%애사서륜%보신익뇌환
Insomnia%Estazolam%Bushenyinaowan
目的 探讨艾司唑仑联合补肾益脑丸对失眠症的临床洽疗效果.方法 选择北京军区总医院第三门诊部就诊的失眠症患者65例(所有患者均符合中国精神疾病分类方案与诊断标准中失眠症的诊断标准,排除有躯体疾病或精神障碍症状导致的继发性失眠及外源性睡眠障碍者).完全随机分为观察组(33例)和对照组(32例).观察组应用艾司唑仑联合补肾益脑丸治疗;对照组服用艾司唑仑单药治疗.分别于治疗前及治疗3个疗程后,采用匹兹堡睡眠质量指数( PSQI)对观察组和对照组的睡眠质量进行评定.结果 65例患者中完成研究62例;发生脱失3例,其中观察组脱失1例、对照组脱失2例,治疗3个疗程后,观察组与对照组比较,PSQI评分总分下降幅度大于对照组,差异有统计学意义(P＜0.05).2组治疗后患者的入睡时间缩短,PSQI评分下降[对照组分别为(2.1±0.5)分比(0.6±0.4)分,观察组分别为(2.1±0.5)分比(0.63±0.41)分],睡眠时间均延长,PSQI评分下降[对照组分别为(1.9±0.3)分比(1.0±0.6)分,观察组分别为(1.9±0.5)分比(0.9±0.6)分],睡眠质量、睡眠效率提高,差异有统计学意义(均P＜0.01).与对照组治疗后比较,观察组患者日间功能障碍减少,差异有统计学意义(P＜0.05).结论 艾司唑仑联合补肾益脑丸治疗失眠症有较好的治疗效果,并能减少艾司唑仑的不良反应.
目的 探討艾司唑崙聯閤補腎益腦汍對失眠癥的臨床洽療效果.方法 選擇北京軍區總醫院第三門診部就診的失眠癥患者65例(所有患者均符閤中國精神疾病分類方案與診斷標準中失眠癥的診斷標準,排除有軀體疾病或精神障礙癥狀導緻的繼髮性失眠及外源性睡眠障礙者).完全隨機分為觀察組(33例)和對照組(32例).觀察組應用艾司唑崙聯閤補腎益腦汍治療;對照組服用艾司唑崙單藥治療.分彆于治療前及治療3箇療程後,採用匹玆堡睡眠質量指數( PSQI)對觀察組和對照組的睡眠質量進行評定.結果 65例患者中完成研究62例;髮生脫失3例,其中觀察組脫失1例、對照組脫失2例,治療3箇療程後,觀察組與對照組比較,PSQI評分總分下降幅度大于對照組,差異有統計學意義(P＜0.05).2組治療後患者的入睡時間縮短,PSQI評分下降[對照組分彆為(2.1±0.5)分比(0.6±0.4)分,觀察組分彆為(2.1±0.5)分比(0.63±0.41)分],睡眠時間均延長,PSQI評分下降[對照組分彆為(1.9±0.3)分比(1.0±0.6)分,觀察組分彆為(1.9±0.5)分比(0.9±0.6)分],睡眠質量、睡眠效率提高,差異有統計學意義(均P＜0.01).與對照組治療後比較,觀察組患者日間功能障礙減少,差異有統計學意義(P＜0.05).結論 艾司唑崙聯閤補腎益腦汍治療失眠癥有較好的治療效果,併能減少艾司唑崙的不良反應.
목적 탐토애사서륜연합보신익뇌환대실면증적림상흡료효과.방법 선택북경군구총의원제삼문진부취진적실면증환자65례(소유환자균부합중국정신질병분류방안여진단표준중실면증적진단표준,배제유구체질병혹정신장애증상도치적계발성실면급외원성수면장애자).완전수궤분위관찰조(33례)화대조조(32례).관찰조응용애사서륜연합보신익뇌환치료;대조조복용애사서륜단약치료.분별우치료전급치료3개료정후,채용필자보수면질량지수( PSQI)대관찰조화대조조적수면질량진행평정.결과 65례환자중완성연구62례;발생탈실3례,기중관찰조탈실1례、대조조탈실2례,치료3개료정후,관찰조여대조조비교,PSQI평분총분하강폭도대우대조조,차이유통계학의의(P＜0.05).2조치료후환자적입수시간축단,PSQI평분하강[대조조분별위(2.1±0.5)분비(0.6±0.4)분,관찰조분별위(2.1±0.5)분비(0.63±0.41)분],수면시간균연장,PSQI평분하강[대조조분별위(1.9±0.3)분비(1.0±0.6)분,관찰조분별위(1.9±0.5)분비(0.9±0.6)분],수면질량、수면효솔제고,차이유통계학의의(균P＜0.01).여대조조치료후비교,관찰조환자일간공능장애감소,차이유통계학의의(P＜0.05).결론 애사서륜연합보신익뇌환치료실면증유교호적치료효과,병능감소애사서륜적불량반응.
Objective To study the clinical effect of insomnia patients treated by estazolam combined with bushenyinaowan.Methods All 65 patients with insomnia were chosen according to the diagnostic criteria of mental disorders;patients with secondary and/or exogenous insomnia were excluded.The 65 cases were randomly divided into 2 groups.33 patients in the observing group received estazolam combined with bushenyinaowan;32 patients in the control group only received estazolam.After 3 courses of treatment,the sleep quality of the 2 groups were assessed according to pittsburge sleep quality index(PSQI).The result ammged from 0 to 21 and the high PSQI point accounted for bad sleep quality.Results After 3 courses of treatment,1 case in the observing group and 2 cases in the control group dropped out;the decrease of PSQI point was significantly higher in observing group than that in control group,P ＜ 0.05.Compared with control group,patients in observing group had less day time function disorders,P ＜ 0.05.Conclusion In insomnia patients,bushenyinaowan and estazolam can bring significant improvement of clinical efficacy and reduce the adverse reaction of estazolam.
